Literature DB >> 2582310

Lesch-Nyhan syndrome: CSF neurotransmitter abnormalities.

F S Silverstein, M V Johnston, R J Hutchinson, N L Edwards.   

Abstract

Serial determinations of spinal fluid homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) were made in four patients with the Lesch-Nyhan syndrome over a 5-year period. Control spinal fluids for age-matched comparison were obtained from 194 neurologic and nonneurologic pediatric patients. A rapid decline in control spinal fluid HVA and 5-HIAA occurs over the first 3 years of life (50 and 60%, respectively), and a more gradual decline persists throughout adolescence. The Lesch-Nyhan subjects have similar age-related changes in their spinal fluid neurotransmitter levels. Sequential 5-HIAA determinations from the four Lesch-Nyhan boys fall within the control range. The Lesch-Nyhan HVA levels are lower than the mean value for the age-matched control group in 18 of 19 samples. Ten of 19 determinations fell below the control range. Our findings provide evidence for altered CNS dopamine metabolism in the Lesch-Nyhan syndrome.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2582310     DOI: 10.1212/wnl.35.6.907

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

Review 1.  Lesch-Nyhan Syndrome: Models, Theories, and Therapies.

Authors:  Scott Bell; Ilaria Kolobova; Liam Crapper; Carl Ernst
Journal:  Mol Syndromol       Date:  2016-09-24

2.  Reduction in serotonin 5HT2 receptor binding on platelets of delinquent adolescents.

Authors:  R Blumensohn; G Ratzoni; A Weizman; M Israeli; N Greuner; A Apter; S Tyano; A Biegon
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

3.  CSF monoamine metabolite concentrations vary according to age, rearing, and sex, and are influenced by the stressor of social separation in rhesus monkeys.

Authors:  J D Higley; S J Suomi; M Linnoila
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  HGprt deficiency disrupts dopaminergic circuit development in a genetic mouse model of Lesch-Nyhan disease.

Authors:  J E Visser; S M Kolk; J S Witteveen; S R Loopstok; L Luque Ballesteros; A Boonstra; N H M van Bakel; W H P van Boekel; G J M Martens
Journal:  Cell Mol Life Sci       Date:  2022-06-04       Impact factor: 9.207

5.  Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo.

Authors:  D F Wong; J C Harris; S Naidu; F Yokoi; S Marenco; R F Dannals; H T Ravert; M Yaster; A Evans; O Rousset; R N Bryan; A Gjedde; M J Kuhar; G R Breese
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

Review 6.  Mouse models of hypoxanthine phosphoribosyltransferase deficiency.

Authors:  D J Williamson; M L Hooper; D W Melton
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

7.  Lesch-Nyhan syndrome and its pathogenesis: purine concentrations in plasma and urine with metabolite profiles in CSF.

Authors:  R A Harkness; G M McCreanor; R W Watts
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

Review 8.  Genotype-phenotype correlations in neurogenetics: Lesch-Nyhan disease as a model disorder.

Authors:  Rong Fu; Irene Ceballos-Picot; Rosa J Torres; Laura E Larovere; Yasukazu Yamada; Khue V Nguyen; Madhuri Hegde; Jasper E Visser; David J Schretlen; William L Nyhan; Juan G Puig; Patrick J O'Neill; H A Jinnah
Journal:  Brain       Date:  2013-08-22       Impact factor: 13.501

Review 9.  Dopamine function in Lesch-Nyhan disease.

Authors:  W L Nyhan
Journal:  Environ Health Perspect       Date:  2000-06       Impact factor: 9.031

Review 10.  Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome.

Authors:  Rosa J Torres; Juan G Puig
Journal:  Orphanet J Rare Dis       Date:  2007-12-08       Impact factor: 4.123

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.